Home >  Investors Relations >  Financial Information >  SEC Filings

News Releases

  • April 1, 2020 at 4:01 PM EDT
    ATLANTA , April 1, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers.
  • March 4, 2020 at 4:05 PM EST
    Newest Hybrid Stent Graft Offering Enhances Ease-of-Use ATLANTA , March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO , a hybrid stent graft system
  • February 27, 2020 at 4:05 PM EST
    ATLANTA , Feb. 27, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union .  The On-X AAP
  • February 13, 2020 at 4:05 PM EST
    ATLANTA , Feb. 13, 2020 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $69.7 million in the fourth quarter of 2019, reflecting year over year growth of 3% and a 4% increase on a non-GAAP constant currency basis, both compared to the fourth quarter of 2018 On-X ®
  • January 30, 2020 at 8:34 AM EST
    ATLANTA , Jan. 30, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday, February 13, 2020 after the market closes.  On that
  • December 23, 2019 at 8:30 AM EST
    Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , Dec. 23, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S.
  • December 19, 2019 at 8:30 AM EST
    CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA , Dec. 19, 2019 /PRNewswire/ --   CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby
  • December 2, 2019 at 8:02 AM EST
    Product Launch Anticipated in the First Quarter 2020 ATLANTA , Dec. 2, 2019 /PRNewswire/ --   CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally
  • December 2, 2019 at 8:00 AM EST
    First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA , Dec. 2, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY),   a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside
  • October 30, 2019 at 4:05 PM EDT
    ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ®